Infections

7
Pipeline Programs
7
Companies
6
Clinical Trials
2 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
CUBICINApproved
daptomycin
Unknown Company
intravenous2003
U
CUBICIN RFApproved
daptomycin
Unknown Company
intravenous2003

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
DaptomycinPhase 31 trial
Active Trials
NCT01184872Completed120Est. Mar 2011
Arrowhead Pharmaceuticals
1 program
1
Azithromycin PillPhase 11 trial
Active Trials
NCT06543290Recruiting400Est. Aug 2026
Sandoz
SandozAustria - Kundl
1 program
1
Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLCPhase 11 trial
Active Trials
NCT00875966CompletedEst. Oct 2004
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
Meropenem-PralubactamPhase 11 trial
Active Trials
NCT07124468RecruitingEst. Feb 2026
CT
1 program
1
The injectable TQD3606Phase 11 trial
Active Trials
NCT05340530UnknownEst. Dec 2023
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Silverlon®N/A1 trial
Active Trials
NCT02781779Completed147Est. Dec 2017
Rhythm Pharmaceuticals
1 program
Silverlon®N/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisDaptomycin
Qilu PharmaceuticalMeropenem-Pralubactam
Arrowhead PharmaceuticalsAzithromycin Pill
Chia Tai TianQing Pharmaceutical GroupThe injectable TQD3606
SandozAzithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC
City TherapeuticsSilverlon®

Clinical Trials (6)

Total enrollment: 667 patients across 6 trials

NCT01184872NovartisDaptomycin

Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections

Start: Mar 2010Est. completion: Mar 2011120 patients
Phase 3Completed
NCT07124468Qilu PharmaceuticalMeropenem-Pralubactam

Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants

Start: Sep 2025Est. completion: Feb 2026
Phase 1Recruiting
NCT06543290Arrowhead PharmaceuticalsAzithromycin Pill

Azithromycin Before Induction

Start: Aug 2023Est. completion: Aug 2026400 patients
Phase 1Recruiting
NCT05340530Chia Tai TianQing Pharmaceutical GroupThe injectable TQD3606

To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects

Start: Apr 2022Est. completion: Dec 2023
Phase 1Unknown
NCT00875966SandozAzithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC

Comparative Bioavailability Study of Azithromycin 200mg/5mL Suspension Following a 600mg Dose Under Fed Conditions

Start: Aug 2004Est. completion: Oct 2004
Phase 1Completed
NCT02781779City TherapeuticsSilverlon®

Comparison of Outcomes Between the Use of Silverlon® Dressing and AQUACEL® AG Dressing Post Cardiac Device Implant

Start: Jun 2016Est. completion: Dec 2017147 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 667 patients
7 companies competing in this space